DBV Technologies says Phase 3 Trial of Viaskin Peanut in Toddlers Met Primary Endpoint

• (PLX AI) - DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers.
• • DBV Technologies says 67.0% of subjects treated with Viaskin Peanut 250 µg met response criteria at 12 months
• • Says trial met primary endpoint: lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 22.4%, exceeding the pre-specified threshold of 15%